The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of durvalumab following multimodality therapy for locally advanced esophageal adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-ESO14-012 study.
 
Hirva Mansurali Mamdani
No Relationships to Disclose
 
Laith I. Abushahin
Research Funding - Merck (Inst); OncoMed (Inst)
 
Bryan J. Schneider
Consulting or Advisory Role - Clovis Oncology; Genentech/Roche
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Macrogenics (Inst); MedImmune (Inst); OncoMed (Inst)
 
Rozina A. Chowdhery
No Relationships to Disclose
 
Borys Hrinczenko
No Relationships to Disclose
 
Ahran Lee
No Relationships to Disclose
 
Susan M. Perkins
No Relationships to Disclose
 
Kenneth Kesler
No Relationships to Disclose
 
Shadia Ibrahim Jalal
Research Funding - AstraZeneca/MedImmune